Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
31 hedge funds and large institutions have $122M invested in Sierra Oncology, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
69% more capital invested
Capital invested by funds: $71.9M → $122M (+$49.9M)
15% more funds holding
Funds holding: 27 → 31 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$7.88M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$2.78M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.05M |
| 4 |
SCM
Sio Capital Management
New York
|
+$923K |
| 5 |
TI
Telemetry Investments
New York
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$4.23M |
| 2 |
Millennium Management
New York
|
-$249K |
| 3 |
Morgan Stanley
New York
|
-$128K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$111K |
| 5 |
A
Abingworth
London,
United Kingdom
|
-$75.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $30K | +$21.1K | +1,521 | +399% |
|
27
BlackRock
New York
| $28K | -$37.3K | -2,684 | -60% |
|
|
28
Morgan Stanley
New York
| $16K | -$128K | -9,248 | -90% |
|
29
Group One Trading
Chicago,
Illinois
| $3K | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $3K | – | – | – |
|
|
RE
31
RBC Europe
London,
United Kingdom
| $385 | – | – | – |
|
|
WG
32
Winton Group
London,
United Kingdom
| – | -$111K | -10,421 | Closed |
|
SRRA Hedge Fund Activity: Q4 2020 in Review
31 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q4 2020, worth a combined $122M — up 69% from $71.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SRRA positions and 2 closed out — a net gain of 4 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Rock Springs Capital Management, opening a new position worth an estimated $7.88M. The largest seller was Mangrove Partners, cutting an estimated $4.23M.
- 31 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q4 2020, up from 27 in Q3 2020.
- Funds reported $122M of Sierra Oncology, Inc. Common Stock stock for Q4 2020, up 69% quarter-over-quarter.
- 6 funds opened new Sierra Oncology, Inc. Common Stock positions in Q4 2020 and 2 closed out, a net change of +4 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q4 2020 was Rock Springs Capital Management, an estimated $7.88M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q4 2020 was Mangrove Partners, an estimated $4.23M sold.
Based on aggregated 13F filings for Q4 2020.